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Purpose: Limited data are available on immunologic responses to primary pandemic H1N1 (2009) 
vaccination in recipients of allogeneic hematopoietic stem cell transplantation (HSCT) recipients. In 
2009 serologic responses to either pandemic H1N1 (2009) vaccine (n = 36) or pandemic H1N1 (2009) 
infection (n = 2) were studied in 38 HSCT recipients. 
 
Methods: Responses were measured with a standard hemagglutination-inhibition assay. Fourteen 
patients had active chronic graft-versus-host disease (cGvHD) at the time of vaccination/infection and 
seven patients had cGvHD in remission; 11 patients had no immunosuppressive therapy, and 27 
patients were on immunosuppressive therapy. Nineteen patients (53%) responded to pandemic H1N1 
(2009) vaccination. Two patients had pandemic H1N1 (2009) infection without prior vaccination, and 
one patient had severe pandemic H1N1 (2009) infection with acute respiratory distress syndrome 
despite prior single vaccination. 
 
Results: Non-responders to pandemic H1N1 (2009) vaccination more often had cGvHD (65 vs. 53%) 
and received second- or third-line therapy (53 vs. 11%), while responders mostly had first-line therapy 
for cGvHD. While vaccine responders had no or single agent immunosuppressive therapy, non-
responders frequently received moderate or intense immunosuppressive therapy. All vaccine 
recipients previously treated with rituximab were non-responders. 
 
Conclusions: In summary, the overall response to pandemic H1N1 (2009) vaccination in HSCT 
recipients was modest. Patients receiving combined immunosuppressive therapy for steroid-refractory 





Patients after allogeneic hematopoietic stem cell transplantation (alloHSCT) are at high risk for 
respiratory viral infections, such as influenza A, parainfluenza and respiratory syncytial virus (RSV). In 
spring 2009, a novel H1N1 influenza A virus caused a pandemic [1]. Following the pandemic, the 
seroprevalence of H1N1 antibodies was 36.9% in healthy people who had not received vaccination, 
with almost 70% of H1N1 (2009) infections being inapparent in healthy people [2]. Pandemic H1N1 
(2009) influenza A infections may lead to severe pneumonia in children and young adults, with 
immunosuppression being an important risk factor [3–5]. Due to the profound immunodeficiency in 
patients after alloHSCT, pandemic H1N1 (2009) influenza A infection causes more severe respiratory 
disease in HSCT recipients than seasonal influenza A and B viruses, with graft-versus-host disease 
(GvHD) being an additional risk factor [6–10]. Therefore, prevention and prophylaxis of infections, 
including re-vaccination, are crucial in this patient group [11]. 
 
Limited data are available on the immunologic responses to primary pandemic H1N1 (2009) infection 
and pandemic H1N1 (2009) vaccination in patients with hematologic malignancies in general and in 
HSCT recipients in particular [12–15]. Here, we present the results of a retrospective analysis of 
pandemic H1N1 (2009) vaccination response in alloHSCT recipients and its correlation with clinical 
and immunological characteristics. 
 
 
Patients and methods 
 
Patients and clinical data 
 
Thirty-eight alloHSCT recipients who received a pandemic H1N1 (2009) AS03-adjuvanted vaccine 
(n = 36; Pandemrix; GlaxoSmithKline, London, UK) or developed pandemic H1N1 (2009) infection 
(n = 2) during the fall of 2009 were included in this retrospective analysis. Blood samples for 
assessment of the vaccine response against H1N1 were obtained during regular visits at the 
outpatient clinic of the department of hematology and oncology at the University Hospital of 
Regensburg. The H1N1 vaccination was given either when the patient visited the outpatient 
department of the University Hospital or by a general practitioner. Twenty-two patients received only 
one dose of pandemic H1N1 vaccine, and 14 patients (39%) were vaccinated twice.  
 
Three patients had proven pandemic H1N1 (2009) influenza infection, one of whom had been 
vaccinated once previously against pandemic H1N1 (2009) virus. Medical records were reviewed, and 
relevant data at the time of vaccination were recorded, including gender, patient age, date of 
alloHSCT, date of pandemic H1N1 (2009) vaccination, time after transplantation, underlying disease, 
current remission status, donor type, HLA-match, stem cell source, and the conditioning regimen. 
For all patients, the grade of prior acute and of prior and current chronic GvHD was documented. 
Acute GvHD (aGvHD) was graded according to the modified Keystone criteria, while chronic GvHD 
(cGvHD) was graded according to the National Institutes of Health standard [16, 17]. The intensity of 
immunosuppression required to control aGvHD was also noted (steroid-sensitive vs. refractory 
aGvHD). In addition, the type of onset of cGvHD (de novo, progressive, or quiescent onset) as well as 
the presence of thrombocytopenia at onset of cGvHD were documented. The number of treatment 
lines to control cGvHD and current intensity of immunosuppression at the time of vaccination were 
documented. 
 
For the statistical analysis, three subcategories of immunosuppression were classified: (1) mild, 
indicating treatment with prednisone alone at a dose <0.5 mg/kg body weight (BW) per day; (2) 
moderate, indicating therapy consisting of prednisone alone at a dose ≥0.5 mg/kg BW per day and/or 
any other single agent of immunosuppressive therapy; (3) intense, consisting of two or more agents 
with or without prednisone in a dose ≥0.5 mg/kg BW per day according to Mitchell et al. [18]. 
Treatment with rituximab was documented separately, and it was noted whether rituximab was 






Lymphocyte subsets and immunoglobulins were measured in all but one patient at the time of 
vaccination. T cell subsets measured were the number of CD3+ cells, CD4+ T cells, CD4+CD45RA+ T 
cells, and CD4+CD45RA−CCR7+CD62L+ central effector memory T cells, as well as CD8+ T cells. B 
cells were determined by differentiating between naïve B cells (CD19+CD27−), immature B cells 
(CD19+CD21−CD27−), and memory B cells (CD19+CD27+). Analyses were performed by flow 
cytometry (FACS) of the peripheral blood, and the absolute values of these parameters were included 
in the statistical analysis. Moreover, the level of gamma-globulins in the serum was documented in 
relation to immunoglobulin-substitution if applicable. 
 
Anti-H1N1 antibody titers were measured using the hemagglutination-inhibition (HI) assay before and 
at least once after vaccination (within 4–8 weeks after vaccination). No serum sample was obtained 
from three patients prior to vaccination. One patient showed no titer after vaccination and was 
classified as a non-responder. One patient was vaccinated twice: his titer after the first vaccination 
was 1:160 and after the second vaccination 1:1280. We therefore assumed a vaccination response 
because of the clear increase in titer after the second vaccination and due to the fact that the maximal 
baseline titer in all of the other patients prior to first vaccination was 1:40 and no other influenza 
vaccination was performed. The third patient showed a titer of 1:960, which was clearly positive and 
most likely not explained by a pre-existing titer. Therefore, this patient was regarded as a vaccination 
responder. A second sample was available for 23 of 38 patients, and a third sample was available for 
four of the 38 patients. Each serum sample was measured twice and the mean value included for 
analysis. 
 
Antibody titers were measured by a HI assay as previously described [19]. Serum samples were pre-
treated with receptor-destroying enzyme for inactivation of non-specific inhibitors. The sera samples 
were then titrated in twofold dilutions in phosphate-buffered saline at an initial dilution of 1:10 up to a 
final dilution of 1:1280. The strain A/California/7/2009 was used as the reference virus and adjusted to 
4 HA units/25 μl, which was verified by back titration, and 25 μl of this virus suspension was added to 
each of the 96 wells. The plates were incubated at room temperature (RT) for 30 min. Freshly 
prepared 0.5% turkey red blood cells were added, followed by a further incubation at RT for 30 min. 
Human sera and an international H1N1 (2009) serum standard serving as positive controls and 
negative controls were included on each plate. 
Titers were expressed as the reciprocal of the highest serum dilution at which hemagglutination was 
prevented. Samples that were negative according to the HI assay were assigned a titer of 1:5 for 
computational purposes in obtain fourfold increase of HI titers. 
Seroconversion was defined as either a pre-vaccination titer of <1:10 together with a post-vaccination 
titer of ≥1:40, or a significant increase in HI titer by a factor of ≥4. Seroprotection was defined as a HI 
titer of 1:40 or higher. 
 
For a more susceptible analysis of vaccination response, patients achieving any response to 
pandemic H1N1 (2009) vaccination were divided into very good responders, responders, and partial 
responders, respectively. Patients failing to achieve any response were classified as non-responders 
(titer <1:10). Partial responders achieved a titer (or an increase in titer) that was lower than 1:40. Very 
good responders were characterized with a titer (or an increase in titer) higher than 1:100, and 
responders showed a titer (or an increase in titer) between 1:40 and 1:100. The group of partial 
responders was included in the analysis since this subgroup would not have been captured by 





The endpoint of the study was the response to pandemic H1N1 (2009) influenza vaccination in 
patients after alloHSCT. A second endpoint was the correlation of the vaccination response with 
clinical and immunological characteristics of these patients. Descriptive analyses were performed in 
Microsoft Excel (Microsoft, Redword, WA). Calculation of the impact of lymphocyte subsets and 
immunoglobulins were performed using SPSS ver. 15 (SPSS, Chicago, IL) by applying the Levene 
test and the t test. Differences in patient characteristics between responders and non-responders were 
evaluated by the chi-square test. In addition, a multi-regression analysis was performed to evaluate 
factors having an impact on the vaccination response, including the intensity of immunosuppression, 
severity of cGvHD, the application of rituximab, and B cell counts at the time of vaccination. 
  
Categorical variables were described as the number and relative frequency (%); continuous variables 







Thirty-eight HSCT recipients (28 unrelated and 10 related) were evaluated with regard to response to 
pandemic H1N1 (2009) vaccination. Thirty-six patients (95%) were vaccinated against H1N1 during 
the fall/winter of 2009, three patients had proven pandemic H1N1 (2009) infection, one patient 
developed severe pandemic H1N1 (2009) infection with acute respiratory distress syndrome (ARDS) 
on post-transplantation day 1902 despite prior single pandemic H1N1 (2009) vaccination 6 weeks prior 
to infection. The other two patients developed H1N1 infection on post-transplantation days 111 and 
321, respectively. All patients with pandemic H1N1 (2009) infection received treatment with 
oseltamivir. 
 
Fourteen patients (39%) received a second vaccination against pandemic H1N1 (2009) virus. The 
median time between vaccination and serum collection was 35 (range 14–70) days. 
 
The grade of acute and chronic GvHD was documented for all patients, as depicted in Table 1. 
Twenty-seven patients (71%) had prior aGvHD, and none had active aGvHD at the time of pandemic 
H1N1 (2009) vaccination. 
 
Table 1 shows the disposition of the different subcategories of immunosuppression among all patients 





Seroconversion (pre-vaccination titer of <1:10 together with a post-vaccination titer of ≥1:40, or a 
significant increase in HI titer by a factor of ≥4) and seroprotection (HI titer of 1:40 or more) rate was 
42% (n = 15/36) after the first pandemic H1N1 (2009) vaccination, increasing to a seroprotection rate 
of 47% (n = 17/36) after the second vaccination. Only 14 of 36 patients received a second vaccination. 
No severe adverse effect was attributable to pandemic H1N1 (2009) vaccination. Two patients had 
pandemic H1N1 (2009) infection without prior vaccination, and one patient developed severe 
pandemic H1N1 (2009) infection with ARDS despite a prior single pandemic H1N1 (2009) vaccination. 
This latter patient was considered to be a non-responder although a serum probe prior to infection was 
not available. Vaccination responders were further distinguished into very good responders (n = 15), 
responders (n = 2), and partial responders (n = 2) (Table 2; Fig. 1). Four partial responders were 
identified after the first vaccination. Three of these had a titer of 1:20, and one had a titer of 1:15, 
indicating failure to achieve seroconversion and/or seroprotection. Two patients in this group were 
vaccinated a second time: one showed an increase in titer from 1:15 to 1:40 (pr− > r), the second from 
1:20 to 1:320 (pr− > vgr), indicating seroprotection. 
 
Of the 19 patients responding to a first dose of pandemic H1N1 (2009) vaccine, seven (37%) received 
a second dose, and two additional patients showing only partial response to the first vaccination 
received a second vaccination with subsequent seroprotection. Of the 17 non-responding patients 
(29%), five showed no response to the second dose. Within the group of responders and very good 
responders, nine of 17 patients (53%) received a second H1N1 vaccine dose (Table 2). 
 
Table 3 summarizes the clinical data for the groups of vaccination responders and non-responders. 
 
Of the 19 responders to vaccination, nine were off immunosuppressive therapy (47%), five (26%) 
received mild immunosuppressive therapy, four (21%) received moderate immunosuppressive 
therapy, and only one patient (5%) received intense immunosuppressive therapy. In the group of non-
responders (n = 17), the majority of patients were on mild or moderate immunosuppressive therapy: 
only two of 17 patients (12%) had had no immunosuppressant therapy, while seven (41%) and six 
(35%) patients received mild and moderate immunosuppressive treatment, respectively. Of the 17 
patients not responding to pandemic H1N1 (2009) vaccination, two (12%) were receiving intense 
immunosuppressive therapy (Fig. 1). The group of very good responders and responders showed a 
  
similar disposition as the vaccination responders in general. 
 
Categorizing the patients according to the underlying immunosuppressive therapy, we found that 82% 
of the patients not receiving immunosuppresssive therapy responded to pandemic H1N1 (2009) 
vaccination. In contrast, decreased responses were found among patients receiving 
immunosuppressive therapy, with the response rate being 42% among patients receiving mild 
immunosuppressive therapy, 40% among those receiving moderate immunosuppressive therapy, and 
33% among those receiving intense immunosuppressive therapy. 
 
The multi-regression analysis revealed that the intensity of the immunosuppression was the most 
important cofactor influencing vaccination response [exp (β) = 0.34, p = 0.064], but it failed to reach 
the significance level due to the limited number of patients. The response to pandemic H1N1 (2009) 
vaccination in correlation to intensity of immunosuppression is shown in Fig. 1. 
 
Of the 17 non-responders, six (35%) had received prior rituximab therapy. Of the three patients with 
proven pandemic H1N1 (2009) infection, two were treated previously with rituximab, and one 
developed pandemic H1N1 (2009) infection despite vaccination 8 months after treatment with 
rituximab without further immunosuppressive treatment. 
 
Interestingly, vaccination responders mostly had a history of grade 1 aGvHD (10/19, 53%) and rarely 
had grade 2 (2/19, 11%) and grade 3 aGvHD (1/19, 5%). In contrast, non-responders more frequently 
had a history of significant aGvHD (grade 1 in 4/17 cases, 24%; grade 2 in 6/17 cases, 35%; grade 3 
in 2/17, 12%). Failure of the primary treatment of aGvHD and subsequent recurrence of aGvHD were 
associated with failure to respond to pandemic H1N1 (2009) vaccination (Table 3). 
 
Non-responders more often had cGvHD at any time after transplantation (65 vs. 53%) and, applying 
the NIH grading of cGvHD, more frequently had moderate and severe cGvHD (responders: 89% with 
no or mild cGvHD and 11% with moderate cGvHD; non-responders: 76% with no or mild cGvHD; 24% 
with moderate or severe cGvHD). Active cGvHD at the time of pandemic H1N1 (2009) vaccination was 
more frequent in non-responders than responders (47 vs. 32%, respectively). While vaccination 
responders with cGvHD mostly had first-line therapy, non-responders received second- or third-line 
therapy for cGvHD (first-line therapy: 32 vs. 12%, respectively). Due to the limited number of patients, 
apart from the effect of time after transplantation, none of the factors reached the significance level 
(Table 3). 
 
Responders had a significant higher number of naïve (CD19+CD27−) and memory B cells 
(CD19+CD27+) as well as gamma-globulins compared to non-responders (Table 4). The significant 
impact of naïve B cells and gamma-globulins persisted after patients receiving prior rituximab therapy 





Our data demonstrate that alloHSCT recipients respond to vaccination against the pandemic H1N1 
(2009) virus. We found a seroconversion and seroprotection rate of 42% (15/36), which is similar to 
rates reported on pandemic H1N1 (2009) vaccination in alloHSCT and autoHSCT patients by Issa 
et al. [13] and Engelhard et al. [15]. Previous studies of pandemic H1N1 (2009) vaccination in healthy 
people showed seroconversion in >90% within 21 days of vaccination [20, 21]. In contrast, Mackay et 
al. [22] found seroprotection in only 27% of patients with hematological malignancies compared to 
50% in patients with solid tumors. Lu et al. [23] recently reported on patients receiving systemic 
immunosuppression and described a seroprotection rate of 76.2% in patients with systemic lupus 
erythematosus after inactivated monovalent A/H1N1 (2009) vaccination. The results of different 
vaccination trials indicate that the risk/benefit ratio favors vaccination and that the furthest time point 
from chemotherapy is the best [24, 25]. 
 
Garland et al. [12] described an impaired immune response to pandemic H1N1 (2009) infection in 13 
patients with hematologic malignancies, including four alloHSCT recipients, and reported a response 
in six of 11 evaluable patients. In our cohort, one patient who had pandemic H1N1 (2009) infection 
after treatment with rituximab four months prior to infection failed to develop an antibody response 
following infection, indicating complete failure of serological response. 
  
 
Fourteen of 36 patients (39%) received a second pandemic H1N1 (2009) vaccination. In this 
subcohort, two patients failing to respond with seroprotection after the first vaccination achieved 
seroprotection after the second dose, indicating a rather quantitative boost effect of the second 
vaccination. However, it can not be excluded that some of the patients failing to respond to the first 
vaccination, but who did not receive a second vaccination, would have achieved seroprotection in 
response to the latter. Similar results have been described by other groups [20]. In 2005, Ljungman et 
al. [26] found that compared to one dose of vaccine, two doses did not improve the vaccination 
response to influenza A/H1N1, A/H3N2, and influenza B in 70 patients with hematological 
malignancies. One dose of seasonal influenza A/H1N1 vaccine is highly immunogenic in adults, while 
two doses will probably be needed in children younger than 9 years [21]. Recent reports support the 
benefit of repeated H1N1 (2009) vaccination, indicating significantly increased HI titers in response to 
the first and second vaccination [15, 27]. 
 
The time post-transplantation was 367 days in responders (range 160–1406 days) and 540 days in 
non-responders (range 154–2893 days) due to a significant longer follow-up in patients with cGvHD in 
the non-responder group. Issa et al. [13] described an increasing vaccination response rate in 
correlation with the length of the time span after transplantation, reflecting improved 
immunoreconstitution; however, the latter is also impaired by cGvHD [28]. 
 
In our cohort, additional risk factors for failure of the vaccination response, in addition to the of 
cGVHD, were advanced treatment line of cGVHD, intensity of immunosuppression, severity of 
cGVHD, and a history of steroid-resistant acute GvHD. Although Issa et al. were not able to show a 
statistically significant influence of the presence of GvHD and concurrent immunosuppressive therapy 
(including prednisone) on the rate of seroprotection against pandemic H1N1 (2009) influenza virus, the 
trends were similar to our results: 59% of patients without GvHD had seroprotective titers, while 44% 
of those with aGvHD or cGvHD had seroprotective titers [13]. 
 
Of note, the pandemic H1N1 (2009) vaccination response rate in patients receiving 
immunosuppressive therapy for cGVHD was in the range of 42–33%, which is significantly lower than 
that in patients with systemic lupus erythematosus at a comparable intensity of immunosuppression, 
indicating an additional effect of the transplantation and cGvHD itself [23]. Issa et al. [13] found lower 
rates of seroprotective titers to pandemic H1N1 (2009) vaccination in patients receiving 
mycophenolate mofetil. 
 
Rituximab is a human–mouse chimeric monoclonal antibody specific for CD20, a surface glycoprotein 
expressed on B lymphocytes. Prior rituximab therapy completely abrogated subsequent vaccination 
response in our cohort, which is in line with other results reported elsewhere [13, 22, 28, 29]. 
Moreover, a patient receiving rituximab as the sole immunosuppressive treatment 8 months before 
being vaccinated against pandemic H1N1 (2009) virus developed life-threatening pandemic H1N1 
(2009) infection despite vaccination, indicating a long-lasting effect of rituximab. As observed in our 
cohort, the use of monoclonal antibodies, such as rituximab, has been associated with severe courses 
of influenza [6–8]. The effect of rituximab is in line with the association of low naïve and memory B cell 
counts with failure to respond to vaccination. B cells begin to recover at the very earliest 6 months 
after treatment, and they do not return to pretreatment levels for up to 1 year [30]. A very poor 
response to seasonal influenza vaccination in patients treated with monoclonal antibodies (rituximab 
or alemtuzumab) for lymphoma has been described by Ljungman et al. [26] and confirmed in patients 
with rheumatoid arthritis [31]. Whether recall antigens can generate an appreciable response to 
influenza vaccination in patients after rituximab therapy, as described by Takata et al., was not 
examined in our cohort [29]. 
 
The central role of B cells in the vaccination response has already been shown by Frasca et al., who 
demonstrated that intrinsic B cell defects in the elderly contribute to reduced antibody responses to 
influenza vaccine [32]. 
 
Interestingly, no correlation was detectable between the serological response rate and T cell counts of 
the peripheral blood. This is in line with a report by Greinix et al. [33] demonstrating a correlation of 
risk for infectious complications with peripheral B cell counts while T cell counts were not associated 
with the risk for infectious complications. The role of B cells is underlined by the impact of the 
immunoglobulin serum level on the vaccination response. The passive transfer of seroprotective HI 
titers by immunglobulin substitution can be excluded by the observation that patients receiving 
  
pandemic H1N1 vaccination following immunoglobulin substitution had no relevant HI titers prior to 
vaccination and that immunoglobulin substitution was a risk factor for failure to respond to vaccination. 
 
 
In summary, the results of this retrospective analysis indicate an efficacy of pandemic H1N1 (2009) 
vaccination in patients after alloHSCT. Major risk factors for failure of the vaccination response are 
intensity of immunosuppression and cGvHD severity. Additional risk factors are a lack of naïve and 
memory B cells as well as low immunoglobulins at the time of vaccination. The complete failure to 
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Tables and Figures 
 
 
Table 1 Clinical data of patients receiving pandemic H1N1 (2009) vaccination 
 
Clinical data Value 
Male sex 22 (61%) 
Age at pandemic H1N1 (2009) vaccination, years, mean (range) 48 (18–68) 




 100–500 days 19 (53%) 
 500–1,000 days 11 (30%) 
 >1,000 days 6 (17%) 
Disease 
 Acute leukemia 21 
 Multiple myeloma 6 
 Non-Hodgkin lymphoma 4 
 Hodgkin’s disease 1 
 Chronic myelogenous leukemia 2 
 Primary myelofibrosis 1 
 Myelodysplasia 1 
Relapse 5 (14%) 
Relapse at time of pandemic H1N1 (2009) vaccination 3 (8%) 
Donor type 
 HLA matched unrelated, donor 20 (56%) 
 HLA mismatched unrelated donor 7 (19%) 
 HLA matched sibling donor 9 (25%) 
Stem cell source 
 PBSCT 35 (97%) 
 Bone marrow 1 (3%) 
Conditioning regime 
 Reduced intensity conditioning (RIC) 29 (81%) 
 Standard 7 (19%) 
Immunoglobulin substitution 14 (39%) 
Prior aGvHD 25 (69%) 
Prior steroid-refractory aGvHD 5 (14%) 
Relapse of aGVHD 5 (14%) 
Chronic GvHD 20 (56%) 
cGvHD 
 Active 14 (39%) 




  11 (31%) 
 Mild immunosuppression 12 (33%) 
 Moderate immunosuppression 10 (28%) 
  
Clinical data Value 
 Intense immunosuppression 3 (8%) 
 Prior treatment with rituximab 6 (17%) 
 <6 months prior to vaccination/infection 5 
 
alloHSCT, allogeneic hematopoietic stem cell transplantation; PBSCT, peripheral blood stem cell 
transplant; aGvHD/cGvHD, acute/chronic graft-versus-host disease 
 




One patient had received rituximab 8 months prior to vaccination but had no immunosuppression at 
the time of pandemic H1N1 (2009) vaccination 
 
Twenty-one patients (55%) had cGvHD each time when tested. The cGvHD grade (NIH) at the time of 
H1N1 (2009) vaccination/infection was: mild in ten patients (26%), moderate in five patients (13%), 
and severe in one patient (3%). Fourteen patients (37%) had active cGvHD, seven patients (18%) had 
inactive cGvHD [defined as complete remission of cGVHD (n = 4) or absence of immunosuppression 





Table 2 Response to pandemic H1N1 (2009) vaccination  
 
Response to pandemic H1N1 (2009) vaccination Value 
Seroconversion 15 (42%) 
Seroprotection after 1st vaccination 15 (42%) 
Seroprotection after 2nd vaccination 17 (47%) 
Responders 19 (53%) 
Partial responders (HI titer 1:10 to <1:40) 2 
Responders (HI titer ≥1:40 to 1:100) 2 
Very good responders (HI titer >1:100) 15 
Second vaccination 9 of 19 (47%) 
Non-responders (HI titer <1:10) 17 (47%) 
Second vaccination 5/17 (29%) 
Pandemic H1N1 (2009) infection 3 (8%) 
Pandemic H1N1 (2009) infection despite vaccination 1 
 
HI Hemagglutination-inhibition (assay) 
 
Data are presented as the number (n) of patients, with the percentage in parentheses—unless 
indicated otherwise 
  
Table 3 Responder versus non-responder after pandemic H1N1 (2009) vaccination  
 
Clinical data Responder (n = 19) Non-responder (n = 17) p value 
Time post-transplantation, median (range) 367 days (160−1,406) 540 days (154−2,893) 0.038 
 100−500 days 12 (63%) 7 (41%)   
 500−1,000 days 5 (26%) 5 (29%)   
 >1,000 days 2 (11%) 5 (29%)   
Prior aGvHD 13 (68%) 12 (71%) 0.867 
Prior aGvHD 
 Grade 1 10 (53%) 4 (24%) 
   Grade 2 2 (11%) 6 (35%) 
 Grade 3 1 (5%)  2 (12%)  
Steroid-refractory aGvHD 1 (5%) 4 (24%) 0.2460 
Relapse of aGVHD 1 (5%) 4 (24%) 0.2460 
Chronic GvHD 10 (53%) 11 (65%) 0.6958 
Actual stage of cGvHD 
 None 12 (63%) 9 (53%) 
  
 Mild 5 (26%) 4 (23%) 
 Moderate 2 (11%) 3 (18%) 
 Severe 0 1 (6%) 
Active cGvHD 6 (32%) 8 (47%) 0.5628 
cGvHD 
 First-line therapy 6 (32%) 2 (12%) 0.0918 
 Second-line therapy 2 (11%) 7 (41%) 0.3011 
 Third-line therapy 0 2 (12%) 0.4050 
Untreated yet 2 (11%) 0 0.4869 
 
Data are presented as the number (n) of patients, with the percentage in parentheses—unless 
indicated otherwise 
  
Table 4 Responder versus non-responder, lymphocyte subsets, and immunoglobulins  
 
Lymphocyte subsets and 
immunoglobulins 
Responder 
(n = 19) 
Non-
responder 
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5 (26%) 9 (53%)   5 (45%)   
  
Figure 1 Serological response [hemagglutination-inhibition (HI) titer] to first pandemic H1N1 (2009) 
vaccination according to intensity of immunosuppression (including mean HI titer)  
  
 
